Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Azelaic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 6/20 | 0.67 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 5/20 | 0.67 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.67 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.67 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.67 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.67 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 5/20 | 0.92 |
| ▸ | LMNA | P02545 | 3/20 | 0.92 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.92 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.92 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.71 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.71 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.71 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.71 |
| ▸ | PPARD | Q03181 | 6/20 | 0.67 |
| ▸ | PPARA | Q07869 | 6/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | TLR2 | O60603 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL688374 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Sebacic Acid SCHEMBL7717227 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Hydrochloric Acid SCHEMBL8921154 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Sebacic Acid SCHEMBL14809040 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Hydrochloric Acid SCHEMBL19210205 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Sebacic Acid SCHEMBL14809563 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Hydrochloric Acid SCHEMBL8922192 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Hydrochloric Acid SCHEMBL7717229 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Sebacic Acid SCHEMBL689154 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Hydrochloric Acid SCHEMBL8923793 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023231317-A1 | NANOFILTRATION MEMBRANE PREPARATION METHOD AND NANOFILTRATION MEMBRANE PREPARED THEREBY | 沃顿科技股份有限公司 | 2023-12-07 | — | — | WO | claimed |
| CN-109161024-B | Alkali-resistant modified polyether block amino silicone oil and preparation method thereof | 清远市宏图助剂有限公司 | 2021-06-15 | — | — | CN | claimed |
| CN-111961426-A | Joint filling sealing material, preparation method and application thereof | 嘉兴市爵拓科技有限公司 | 2020-11-20 | — | — | CN | claimed |
| CN-105693612-B | Bridging type arylpyrazole type amide compound and its solvent heat one-pot synthesis method and application | 中南民族大学 | 2019-01-08 | — | — | CN | claimed |
| EP-0161549-B1 | ACID HALIDE FUNCTIONAL MATERIALS | DSM RIM NYLON V.O.F (NL) | 1988-11-17 | — | — | EP | claimed |
| EP-0067695-B1 | PROCESS FOR THE PREPARATON OF NYLON BLOCK POLYMERS | DSM RIM NYLON V.O.F (NL) | 1986-10-15 | — | — | EP | claimed |
| EP-0067693-B1 | ACID HALIDE AND ACYLLACTAM FUNCTIONAL MATERIALS | DSM RIM NYLON V.O.F (NL) | 1986-09-10 | — | — | EP | claimed |
| US-4590243-A | USING ACYLLACTAM FUNCTIONAL MATERIALS | MONSANTO COMPANY (US) | 1986-05-20 | — | — | US | claimed |
| US-4590244-A | CHEMICAL INTERMEDIATES FOR NYLON BLOCK POLYMERS | MONSANTO COMPANY (US) | 1986-05-20 | — | — | US | claimed |
| US-4581419-A | POLYMERS HAVING HYDROXY END GROUPS MODIFIED BY A DICARBOXYLIC ACIDAND A LACTAM; NYLON MOLDING MATERIALS | MONSANTO COMPANY (US) | 1986-04-08 | — | — | US | claimed |
| EP-0161549-A1 | Acid halide functional materials | DSM RIM NYLON V.O.F (NL) | 1985-11-21 | — | — | EP | claimed |
| EP-0067695-A1 | Process for the preparaton of nylon block polymers | DSM RIM NYLON V.O.F (NL) | 1982-12-22 | — | — | EP | claimed |
| EP-0067693-A1 | Acid halide and acyllactam functional materials | DSM RIM NYLON V.O.F (NL) | 1982-12-22 | — | — | EP | claimed |
| JP-63198674-A | — | — | None | — | — | JP | disclosed |
| US-20260117059-A1 | CURABLE RESIN, CURABLE RESIN COMPOSITION, CURED PRODUCT, PREPREG, LAMINATE, AND SEMICONDUCTOR SUBSTRATE | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2026-04-30 | — | — | US | disclosed |
| US-20260109854-A1 | CURABLE RESIN COMPOSITION, AND CURED PRODUCT THEREOF | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2026-04-23 | — | — | US | disclosed |
| EP-0148149-A2 | High concentration encapsulation by interfacial polycondensation | Monsanto Company (US) | 1985-07-10 | — | — | EP | disclosed |
| EP-0067695-A1 | Process for the preparaton of nylon block polymers | DSM RIM NYLON V.O.F (NL) | 1982-12-22 | — | — | EP | disclosed |
| EP-0067694-A1 | Acid halide and acyllactam functional materials and process for the preparation of nylon block polymers therewith | DSM RIM NYLON V.O.F (NL) | 1982-12-22 | — | — | EP | disclosed |
| EP-0067693-A1 | Acid halide and acyllactam functional materials | DSM RIM NYLON V.O.F (NL) | 1982-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109854-A1 | CURABLE RESIN COMPOSITION, AND CURED PRODUCT THEREOF | MLLT1, CRBN, POT1 | PPARG 3473/4885HDAC11 670/4885ESR1 385/4885 |
| US-20260117059-A1 | CURABLE RESIN, CURABLE RESIN COMPOSITION, CURED PRODUCT, PREPREG, LAMINATE, AND SEMICONDUCTOR SUBSTRATE | RAD51, ASH2L, H1-0 | PPARG 3637/4885HDAC11 1482/4885ESR1 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.